Semaglutide After Bariatric Surgery
Quick Facts
What Did The Semaglutide Bariatric Surgery Trial Find?
The BARI-STEP trial, published in Nature Medicine, enrolled adults at least one year after gastric bypass or sleeve gastrectomy who had lost less than 20% of their body weight after surgery. Participants were randomly assigned to semaglutide 2.4 mg once weekly or placebo, alongside lifestyle support and a reduced-calorie plan.
Researchers reported a large treatment difference in percentage weight loss favoring semaglutide, with improvements also seen in metabolic measures and weight-related quality of life. The results matter because poor response or later weight regain after bariatric surgery can bring back diabetes, hypertension, sleep apnea and other obesity-related risks.
Why Might GLP-1 Drugs Help After Bariatric Surgery?
Bariatric surgery changes gut hormone signaling, stomach capacity, appetite regulation and glucose metabolism, but responses vary widely between patients. Semaglutide acts as a GLP-1 receptor agonist, a drug class that reduces appetite, slows gastric emptying and improves glucose regulation through pathways already central to obesity treatment.
The study suggests that pharmacotherapy can be used as an adjunct rather than a replacement for surgical care. For some patients, a medication strategy may be less invasive than revisional bariatric surgery, though clinicians still need to assess nutrition, protein intake, muscle preservation, gastrointestinal adverse effects and contraindications such as personal risk factors for pancreatitis or gallbladder disease.
Should Patients Who Regain Weight After Surgery Ask About Semaglutide?
The findings do not mean every patient after bariatric surgery should receive semaglutide. A careful evaluation is needed to identify causes of weight regain, including dietary patterns, medication effects, anatomical issues, mental health factors, sleep disorders and changes in physical activity.
Semaglutide is already approved for chronic weight management in adults with obesity or overweight with weight-related conditions, but post-bariatric patients need individualized follow-up. Long-term questions remain about durability after stopping treatment, access and cost, optimal sequencing with surgery, and how best to preserve lean mass during substantial weight loss.
Frequently Asked Questions
Semaglutide 2.4 mg is approved for chronic weight management in eligible adults, but this specific post-bariatric use should be guided by a clinician familiar with obesity medicine and bariatric follow-up.
No. Weight loss after bariatric surgery varies, and poor response or regain can reflect biology, anatomy, medications, behavior, or other health conditions. Medical therapy may be one tool to improve long-term outcomes.
GLP-1 drugs commonly cause gastrointestinal effects such as nausea, vomiting, diarrhea or constipation. Clinicians also monitor for dehydration, gallbladder problems, pancreatitis symptoms and nutritional issues after bariatric surgery.
References
- Nature Medicine. Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial. 2026.
- ClinicalTrials.gov. NCT05073835: Semaglutide 2.4 mg in Patients With Poor Weight-loss Following Bariatric Surgery.
- Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.